These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 9138599

  • 21. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
    Dogliotti L, Danese S, Berruti A, Zola P, Buniva T, Bottini A, Richiardi G, Moro G, Farris A, Baù MG, Porcile G.
    Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
    [Abstract] [Full Text] [Related]

  • 22. Potentiation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer.
    Orlandi L, Zaffaroni N, Gornati D, Veneroni S, Silvestrini R.
    Anticancer Res; 1994; 14(3A):1161-4. PubMed ID: 8074467
    [Abstract] [Full Text] [Related]

  • 23. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
    Ayash L, Korbut T, Herman TS, Teicher BA.
    Cancer Lett; 1991 Dec 09; 61(1):7-14. PubMed ID: 1764699
    [Abstract] [Full Text] [Related]

  • 24. Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer.
    Bottalico C, Lorusso V, Brandi M, Micelli G, Rella CA, Coviello M, Atlante AM, Quaranta M, De Lena M.
    Anticancer Res; 1996 Dec 09; 16(6B):3865-9. PubMed ID: 9042272
    [Abstract] [Full Text] [Related]

  • 25. In vitro combined effect of a new series of copper (II) complexes with cisplatin or epirubicin on human breast and cervical cancer cell lines.
    Geromichalos GD, Katsoulos GA, Hadjikostas CC, Kortsaris AH, Kyriakidis DA.
    Drugs Exp Clin Res; 1998 Dec 09; 24(2):93-104. PubMed ID: 9675550
    [Abstract] [Full Text] [Related]

  • 26. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G, D'Aiuto G, Comella P, Apicella A, Thomas R, Capasso I, Di Bonito M, Cartenì G, Biglietto M, De Lucia L, Maiorino L, Piccolo S, Bianchi U, D'Aniello R, Lapenta L, Comella G.
    Breast Cancer Res Treat; 1999 Aug 09; 56(3):239-52. PubMed ID: 10573115
    [Abstract] [Full Text] [Related]

  • 27. Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells.
    Sica G, Lama G, Iacopino F, Angelucći C, Della Cuna GR, Marchetti P.
    Anticancer Res; 1991 Aug 09; 11(6):2099-102. PubMed ID: 1776846
    [Abstract] [Full Text] [Related]

  • 28. Kinetic and survival response of the M14 cell line to lonidamine associated with adriamycin or hyperthermia.
    Starace G, Badaracco G, Bertuzzi A, Gandolfi A, Greco C, Totaro MD, Vitelli R, Zupi G.
    J Cancer Res Clin Oncol; 1987 Aug 09; 113(5):451-8. PubMed ID: 3624301
    [Abstract] [Full Text] [Related]

  • 29. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG).
    Buccheri G, Ferrigno D.
    Eur J Cancer; 1994 Aug 09; 30A(10):1424-31. PubMed ID: 7833096
    [Abstract] [Full Text] [Related]

  • 30. Saporin 6 and lonidamine in primary cell cultures from human breast carcinomas: a synergistic effect.
    Gasperi-Campani A, Roncuzzi L, Zoli W, Amadori D.
    Anticancer Drug Des; 1997 Mar 09; 12(2):91-8. PubMed ID: 9113064
    [Abstract] [Full Text] [Related]

  • 31. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study.
    De Lena M, Lorusso V, Latorre A, Fanizza G, Gargano G, Caporusso L, Guida M, Catino A, Crucitta E, Sambiasi D, Mazzei A.
    Eur J Cancer; 2001 Feb 09; 37(3):364-8. PubMed ID: 11239758
    [Abstract] [Full Text] [Related]

  • 32. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
    Wawruszak A, Luszczki JJ, Grabarska A, Gumbarewicz E, Dmoszynska-Graniczka M, Polberg K, Stepulak A.
    PLoS One; 2015 Feb 09; 10(11):e0143013. PubMed ID: 26580554
    [Abstract] [Full Text] [Related]

  • 33. Comparison of action of the anti-neoplastic drug lonidamine on drug-sensitive and drug-resistant human breast cancer cells: 31P and 13C nuclear magnetic resonance studies.
    Vivi A, Tassini M, Ben-Horin H, Navon G, Kaplan O.
    Breast Cancer Res Treat; 1997 Mar 09; 43(1):15-25. PubMed ID: 9065595
    [Abstract] [Full Text] [Related]

  • 34. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
    Buccheri G, Ferrigno D, Rosso A.
    Cancer; 1993 Sep 01; 72(5):1564-72. PubMed ID: 8394198
    [Abstract] [Full Text] [Related]

  • 35. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
    Amadori D, Frassineti GL, De Matteis A, Mustacchi G, Santoro A, Cariello S, Ferrari M, Nascimben O, Nanni O, Lombardi A, Scarpi E, Zoli W.
    Breast Cancer Res Treat; 1998 Jun 01; 49(3):209-17. PubMed ID: 9776504
    [Abstract] [Full Text] [Related]

  • 36. Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole.
    Barberi-Heyob M, Griffon G, Merlin JL, Weber B.
    Cancer Chemother Pharmacol; 1993 Jun 01; 33(2):163-70. PubMed ID: 8261577
    [Abstract] [Full Text] [Related]

  • 37. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis.
    Perez EA, Hack FM, Webber LM, Chou TC.
    Cancer Chemother Pharmacol; 1993 Jun 01; 33(3):245-50. PubMed ID: 8269606
    [Abstract] [Full Text] [Related]

  • 38. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E.
    Cancer Chemother Pharmacol; 2006 Apr 01; 57(4):491-9. PubMed ID: 16075278
    [Abstract] [Full Text] [Related]

  • 39. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
    Schwartz GN, Teicher BA, Eder JP, Korbut T, Holden SA, Ara G, Herman TS.
    Cancer Chemother Pharmacol; 1993 Apr 01; 32(6):455-62. PubMed ID: 8258194
    [Abstract] [Full Text] [Related]

  • 40. In-vitro effect of a combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) on human gastric cancer cell lines: timing of cisplatin treatment.
    Cho H, Imada T, Oshima T, Shiozawa M, Rino Y, Takanashi Y.
    Gastric Cancer; 2002 Apr 01; 5(1):43-6. PubMed ID: 12021859
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.